References
- Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003;21:2138-46
- Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553-61
- Pinilla-Ibarz J, Cortes J. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer 2011;117:688-97
- Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118:4554-60
- Efficace F, Cardoni A, Cottone F, et al. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res 2013;37:206-13
- Phillips KM, Pinilla Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 2013;21:1097-103
- Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia: association of treatment satisfaction, negative medication experience and treatment restrictions with health outcome, from patient’s perspective. Health Qual Life Outcomes 2013;11:167
- Guerin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin 2014;30:2317-28
- Kekale M, Peltoniemi M, Airaksinen M. Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 2015;9:1733-40
- Lutge I, Pfirrmann M, Stalljann I, et al. Health-related quality of life in CML patients under nilotinib first-line treatment: results of a German sub-study within the ENEST1st trial. Haematologica 2015;100(Suppl 1):abstract 233
- Labeit AM, Copland M, Cork LM, et al. Assessment of quality of life in the NCRI Spirit 2 study comparing imatinib and dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood 2015;126:abstract 4024
- Trask PC, Cella D, Besson N, et al. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 2012;36:438-42
- Whiteley J, Reismann A, Shapiro M, et al. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin. 2016 May 5: 1-9. [Epub ahead of print]
- Efficace F, Cocks K, Breccia M, et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2012;81:123-35